The Association of the British Pharmaceutical Industry (ABPI) and the UK government have been unable to reach an agreement on changes to a controversial medicines payment scheme. 

In April 2025, the ABPI and government agreed to bring forward a planned mid-scheme review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG). 

This review was tasked with finding a mutually agreed way to address soaring VPAG payment rates, which now require pharmaceutical companies to make payments up to a quarter to a third (23.5%-35.6%) of their revenue from sales of branded medicines to the NHS. 

The industry and government have not been able to reach an agreed way forward to restore internationally competitive payment rates on medicines sales to the NHS, nor address the way in which National Institute of Health and Care Excellence (NICE) values innovation. 

Richard Torbett, Chief Executive of the ABPI said: “We need to reach a solution that improves patient access to future innovation, allows the sector to fulfil its growth potential, and does not require industry to pay back nearly three times as much of its revenues as is required in other European countries. 

“The NHS’s demand for innovative medicines has continued to grow in line with health demands. Yet the UK’s willingness to invest in new treatments has continued to fall, driven by uncompetitive and punitive rebates on company revenues, and cost-effectiveness thresholds used by the decision-making body NICE that have not fundamentally changed for nearly a quarter of a century. 

“For too long, the UK has sought to be the place where innovation happens, but not the place where it is used. Without change, the UK will continue to fall down international league tables for research, investment, and patient access to medicines.”

Diana Turner, Senior Digital Content Editor, DDW